Biotech Investment Analyst - Remote, Rubric & Asset Eval

Mercor; United States; Remote; USD 83,000 - 152,000; Part time

Benefits offered by this job

Paid pilot

Potential ongoing engagement

Job summary

Mercor is seeking a biotech investment analyst for a paid pilot, focusing on expert evaluation of drugs and development programs. You will create and critique rubrics, assess mechanism, data, and value drivers, and judge investment theses across a small set of companies.

The role is US-based, remote, with ~10-20 hours over 1–2 weeks and potential for ongoing work for strong contributors. You will work with a team to refine AI-driven drug evaluation processes.

Qualifications

• US-based biotech/healthcare investment analyst with a specialist-fund background.
• Familiarity with biotech/pharma development programs.
• Able to assess a drug asset and the company behind it end-to-end.
• 5+ years evaluating biotech/pharma companies or assets.

Responsibilities

• Create and critique rubrics that analyze commercial drugs and drug-development programs.
• Provide overall company and asset assessment - mechanism, clinical data, competitive position, and value drivers.
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions.
• Apply your assessment across the pilot's set of companies (~5-10)

Skills

Investment analysis

Biotech/pharma knowledge

Asset evaluation

Rubric development

Education

Bachelor's degree in a related field

Tools

Excel

Financial modeling

Job description

Mercor is seeking a biotech investment analyst for a paid pilot, focusing on expert evaluation of drugs and development programs. You will create and critique rubrics, assess mechanism, data, and value drivers, and judge investment theses across a small set of companies.

The role is US-based, remote, with ~10-20 hours over 1–2 weeks and potential for ongoing work for strong contributors. You will work with a team to refine AI-driven drug evaluation processes.